ReviewAnnals of neurology2013
Novel approaches and challenges to treatment of central nervous system viral infections.
Review in Annals of neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Chronic Neuroplasticity Changes Following Neurotropic Viral Infection: Mechanisms and Implications.Cellular and molecular neurobiology · 2025Review
- West Nile Virus: An Update Focusing on Southern Europe.Microorganisms · 2024Review
- Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review.Viruses · 2023Review
- European College of Equine Internal Medicine consensus statement on equine flaviviridae infections in Europe.Journal of veterinary internal medicine · 2022Article
- A Nanobody-Mediated Virus-Targeting Drug Delivery Platform for the Central Nervous System Viral Disease Therapy.Microbiology spectrum · 2021Article
- Review
- Human Beta-Defensin 2 and 3 Inhibit HIV-1 Replication in Macrophages.Frontiers in cellular and infection microbiology · 2021Article
- Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules.Molecules (Basel, Switzerland) · 2020Review
- A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019Review
- Article
- New advances in CNS immunity against viral infection.Current opinion in virology · 2018Review
- Potential role of CSF cytokine profiles in discriminating infectious from non-infectious CNS disorders.PloS one · 2018Article
- Grand Challenges in Neuroinfectious Diseases.Frontiers in neurology · 2017Article
- Vaccinations for Neuroinfectious Disease: A Global Health Priority.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells.The Journal of experimental medicine · 2015Article
- Viral diseases of the central nervous system.Current opinion in virology · 2015Review
- Neuroinfectious diseases: a crisis in neurology and a call for action.JAMA neurology · 2015Article
- How to approach and treat viral infections in ICU patients.BMC infectious diseases · 2014Review
- West Nile virus state of the art report of MALWEST Project.International journal of environmental research and public health · 2013Review
- Pathogenic characteristics of central nervous system infections in AIDS individuals: a retrospective cohort study based on immune status.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Existing and emerging viral central nervous system (CNS) infections are major sources of human morbidity and mortality. Treatments of proven efficacy are currently limited predominantly to herpesviruses and human immunodeficiency virus (HIV). Development of new therapies has been hampered by the lack of appropriate animal model systems for some important viruses and by the difficulty in conducting human clinical trials for diseases that may be rare, or in the case of arboviral infections, often have variable seasonal and geographic incidence. Nonetheless, many novel approaches to antiviral therapy are available, including candidate thiazolide and pyrazinecarboxamide derivatives with potential broad-spectrum antiviral efficacy. New herpesvirus drugs include viral helicase-primase and terminase inhibitors. The use of antisense oligonucleotides and other strategies to interfere with viral RNA translation has shown efficacy in experimental models of CNS viral disease. Identifying specific molecular targets within viral replication cycles has led to many existing antiviral agents and will undoubtedly continue to be the basis of future drug design. A promising new area of research involves therapies based on enhanced understanding of host antiviral immune responses. Toll-like receptor agonists and drugs that inhibit specific cytokines as well as interferon preparations have all shown potential therapeutic efficacy. Passive transfer of virus-specific cytotoxic T lymphocytes has been used in humans and may provide an effective therapy for some herpesvirus infections and potentially for progressive multifocal leukoencephalopathy. Humanized monoclonal antibodies directed against specific viral proteins have been developed and in several cases evaluated in humans in settings including West Nile virus and HIV infection and in pre-exposure prophylaxis for rabies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.